• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Alnylam Pharmaceuticals Inc.

    4/1/24 4:34:55 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNY alert in real time by email
    DEFA14A 1 d761542ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    Alnylam Pharmaceuticals, Inc.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


    LOGO

    Your Vote Counts! ALNYLAM PHARMACEUTICALS, INC. 2024 Annual Meeting Vote by May 15, 2024 11:59 PM ET. For shares held in a 401(k) Plan, vote by May 13, 2024 11:59 PM ET. ALNYLAM PHARMACEUTICALS, INC. ATTN: SECRETARY 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE, MA 02142 V36688-P08487-Z87180 You invested in ALNYLAM PHARMACEUTICALS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 16, 2024. Get informed before you vote View the Proxy Statement, Annual Report on Form 10-K and Annual Report to Stockholders online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 2, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* May 16, 2024 10:30 a.m., Eastern Time Virtually at: www.virtualshareholdermeeting.com/ALNY2024 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items 1. To elect the following nominees as Class II directors of Alnylam: Nominees: 1a. Dennis A. Ausiello, M.D. 1b. Olivier Brandicourt, M.D. 1c. Peter N. Kellogg 1d. David E.I. Pyott 2. To approve, in a non-binding advisory vote, the compensation of Alnylam’s named executive officers. 3. To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam’s independent auditors for the fiscal year ending December 31, 2024. In their discretion, the Proxies are authorized to vote upon any other business that may properly come before the annual meeting or at any adjournment(s) thereof. Board Recommends For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V36689-P08487-Z87180

    Get the next $ALNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNY

    DatePrice TargetRatingAnalyst
    1/28/2026$527.00Overweight
    Barclays
    1/7/2026$500.00Outperform
    Oppenheimer
    8/4/2025Underperform → Peer Perform
    Wolfe Research
    8/4/2025$490.00Perform → Outperform
    Oppenheimer
    7/30/2025$370.00Outperform
    Raymond James
    7/21/2025$385.00Buy
    Truist
    3/31/2025$353.00Buy
    Redburn Atlantic
    3/24/2025$280.00 → $328.00Neutral → Overweight
    Analyst
    More analyst ratings

    $ALNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP Chief R&D Garg Pushkal sold $547,929 worth of shares (1,510 units at $362.87) and was granted 3,800 shares, increasing direct ownership by 11% to 22,511 units (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    1/14/26 4:23:29 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Greenstreet Yvonne sold $3,475,157 worth of shares (9,577 units at $362.86) and was granted 19,003 shares, increasing direct ownership by 14% to 78,411 units (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    1/14/26 4:23:05 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Financial Officer Poulton Jeffrey V. was granted 6,193 shares and sold $1,008,766 worth of shares (2,780 units at $362.87), increasing direct ownership by 6% to 57,465 units (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    1/14/26 4:22:39 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    SEC Filings

    View All

    SEC Form 10-K filed by Alnylam Pharmaceuticals Inc.

    10-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    2/12/26 8:12:30 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    2/12/26 8:05:43 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    1/12/26 7:30:20 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

    − Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth Compared to Same Periods in 2024 – − Attained GAAP and non-GAAP Profitability for Full Year 2025, with Sustainable Growth in Operating Income Expected – − Launched "Alnylam 2030" Strategy Focused on Scaling Alnylam through Durable ATTR Leadership, Long-Term Sustainable Innovation, and Exceptional Financial Results – − Announced 2026 Pipeline Goals, Including 4 Clinical Readouts, 3 Ongoing Pivotal Studies, 3 Phase 2 Study Initiations, and 3+ New IND Filings – − Reiterates Net Product Sales Guidance and Provides Additional 2026 Fin

    2/12/26 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2025 on Thursday, February 12, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2025 results as well as expectations for the future via conference call on Thursday, February 12, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the

    1/29/26 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact

    − Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487 Million (103% Growth vs. 2024) – − Company Provides 2026 Combined Net Product Revenue Guidance of $4,900 Million to $5,300 Million, Driven Primarily by Total TTR Net Product Revenue Guidance of $4,400 Million to $4,700 Million – – 2026 Pipeline Goals Focused on Continued Advancement of Numerous Multi-Billion-Dollar Opportunities – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, "Alnylam 2030," focused on scaling the Company's operations through achieving

    1/11/26 5:00:00 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Alnylam Pharma with a new price target

    Barclays resumed coverage of Alnylam Pharma with a rating of Overweight and set a new price target of $527.00

    1/28/26 7:15:18 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Alnylam Pharma with a new price target

    Oppenheimer resumed coverage of Alnylam Pharma with a rating of Outperform and set a new price target of $500.00

    1/7/26 9:00:36 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharma upgraded by Wolfe Research

    Wolfe Research upgraded Alnylam Pharma from Underperform to Peer Perform

    8/4/25 8:14:44 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

    4/30/24 1:44:03 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling

    9/20/23 2:36:38 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling

    2/17/23 12:30:09 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Reitan Colleen F bought $10,363 worth of shares (36 units at $287.85), sold $8,383 worth of shares (36 units at $232.86) and was granted 775 shares (SEC Form 4)

    4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)

    5/12/25 4:05:00 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    11/12/24 9:50:12 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    11/8/24 10:34:33 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

    SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)

    8/12/24 9:40:06 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Leadership Updates

    Live Leadership Updates

    View All

    Alnylam Pharmaceuticals Announces Changes to Board of Directors

    – Mike Bonney and Carolyn Bertozzi to Depart; Company Appoints Stuart Arbuckle as New Independent Director – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of a new independent director. Mike Bonney and Carolyn Bertozzi, Ph.D., who have served in key roles on Alnylam's Board, stepped down effective December 2, 2025. Mr. Bonney joined our Board in 2014 and served as Board Chair from December 2015 to August 2021 and as Executive Chair from August 2021 to January 2023. He helped to guide the company through major milestones and significant growt

    12/3/25 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

    Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

    9/18/25 9:15:00 AM ET
    $ALNY
    $ILMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has

    3/5/25 7:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    Financials

    Live finance-specific insights

    View All

    Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

    − Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth Compared to Same Periods in 2024 – − Attained GAAP and non-GAAP Profitability for Full Year 2025, with Sustainable Growth in Operating Income Expected – − Launched "Alnylam 2030" Strategy Focused on Scaling Alnylam through Durable ATTR Leadership, Long-Term Sustainable Innovation, and Exceptional Financial Results – − Announced 2026 Pipeline Goals, Including 4 Clinical Readouts, 3 Ongoing Pivotal Studies, 3 Phase 2 Study Initiations, and 3+ New IND Filings – − Reiterates Net Product Sales Guidance and Provides Additional 2026 Fin

    2/12/26 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2025 on Thursday, February 12, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2025 results as well as expectations for the future via conference call on Thursday, February 12, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the

    1/29/26 8:00:00 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annual Changes to the Nasdaq-100 Index®

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December 22, 2025. The following six companies will be added to the Index: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Ferrovial SE (NASDAQ:FER), Insmed Incorporated (NASDAQ:INSM), Monolithic Power Systems, Inc. (NASDAQ:MPWR), Seagate Technology Holdings plc (NASDAQ:STX), Western Digital Corp. (NASDAQ:WDC). The Nasdaq-100 Index is a globally recognized index that tracks the performance of 100 of the largest non-financial companies listed on the Nasdaq Stock Market® encompassi

    12/12/25 8:00:00 PM ET
    $ALNY
    $BIIB
    $CDW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Retail: Computer Software & Peripheral Equipment